Rockefeller Capital Management L.P. Raises Holdings in Illumina, Inc. (NASDAQ:ILMN)

Rockefeller Capital Management L.P. lifted its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 6.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 185,220 shares of the life sciences company's stock after purchasing an additional 10,568 shares during the quarter. Rockefeller Capital Management L.P. owned 0.12% of Illumina worth $24,751,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of ILMN. Golden State Wealth Management LLC purchased a new stake in shares of Illumina during the fourth quarter valued at $32,000. Versant Capital Management Inc grew its stake in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after acquiring an additional 146 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Illumina during the fourth quarter valued at approximately $45,000. Assetmark Inc. boosted its holdings in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after purchasing an additional 296 shares during the last quarter. Finally, Lee Danner & Bass Inc. bought a new stake in Illumina in the 4th quarter worth approximately $48,000. Institutional investors own 89.42% of the company's stock.

Analysts Set New Price Targets

ILMN has been the subject of several research analyst reports. Piper Sandler lifted their price objective on Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. HSBC cut shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective on the stock. in a research note on Friday, February 28th. Stephens restated an "overweight" rating and set a $156.00 target price on shares of Illumina in a research note on Tuesday, March 11th. Barclays dropped their price target on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a research report on Thursday, April 10th. Finally, Citigroup reduced their price objective on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research note on Monday, April 7th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $138.70.

Illumina Trading Down 3.2 %

Shares of NASDAQ:ILMN traded down $2.32 during trading on Friday, reaching $71.21. The company's stock had a trading volume of 2,639,652 shares, compared to its average volume of 2,271,527. The firm's 50 day simple moving average is $84.61 and its two-hundred day simple moving average is $120.40. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The stock has a market capitalization of $11.27 billion, a PE ratio of -9.27, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, research analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.